{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:29:53Z","timestamp":1761006593913,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Ferritin is a hallmark biomarker of systemic inflammation in adult-onset Still\u2019s disease (AOSD), but its potential role in guiding escalation to advanced therapy has not been established. This study aimed to evaluate whether ferritin, alone or in combination with simple clinical variables, could predict the need for advanced therapy in AOSD. Methods: A retrospective review was conducted of 113 patients with AOSD fulfilling the Yamaguchi criteria at Chonnam National University Hospital. Baseline demographic, clinical, and laboratory data were collected at the index episode. The primary endpoint was defined as the use of advanced therapy\u2014namely, intravenous immunoglobulin (IVIG), anakinra, or tocilizumab\u2014during the index hospitalization. Ferritin was log-transformed and analyzed both as a continuous variable and in quartiles. A pragmatic Ferritin-Guided Escalation Rule (FGER) points score was constructed by combining ferritin quartiles with malignancy and ANA status. Logistic regression, Fisher\u2019s exact test, and bootstrapped receiver operating characteristic (ROC) analyses were applied. Results: The cohort was predominantly male (64.6%) with a mean age of 44.9 years. Median ferritin was 4626.6 \u00b5g\/L (IQR 1169.3\u201314,239.8). Advanced therapy was required in 15 patients (13.3%), including 14 who received tocilizumab, 1 IVIG, and 1 anakinra. When stratified by ferritin quartiles, advanced therapy occurred in 10.7% of Q1, 21.4% of Q2, 10.7% of Q3, and 10.7% of Q4 patients. Comparison of Q4 versus Q1\u2013Q3 yielded an odds ratio of 0.67 (p = 0.47). Discriminatory performance was poor for both continuous ferritin (AUC 0.49, 95% CI 0.30\u20130.68) and the FGER points score (AUC 0.51, 95% CI 0.32\u20130.71). Calibration analysis also demonstrated limited agreement between predicted and observed risks. Conclusions: In this retrospective cohort, ferritin\u2014whether assessed continuously, by quartiles, or within a simple bedside score\u2014did not predict the need for advanced therapy (IVIG, anakinra, or tocilizumab) in AOSD. Although advanced therapies were administered to 13.3% of patients, ferritin was not a reliable escalation biomarker.<\/jats:p>","DOI":"10.3390\/diagnostics15202630","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:23:34Z","timestamp":1760952214000},"page":"2630","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Hyperferritinemia: Evaluating Ferritin as a Predictor of Advanced Therapy in Adult-Onset Still\u2019s Disease"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-2001","authenticated-orcid":false,"given":"Ji-Hyoun","family":"Kang","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chonnam National University Hospital & Medical School, Gwangju 61469, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.30.2.121","article-title":"Still\u2019s disease in the adult","volume":"30","author":"Bywaters","year":"1971","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still\u2019s disease","volume":"13","author":"Jamilloux","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.bor.0000381996.69261.71","article-title":"Macrophage activation syndrome: Advances towards understanding pathogenesis","volume":"22","author":"Grom","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00005792-200205000-00003","article-title":"Proposal for a new set of classification criteria for adult-onset Still\u2019s disease","volume":"81","author":"Fautrel","year":"2002","journal-title":"Medicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1038\/s41598-019-44032-6","article-title":"Histopathology and expression of the chemokines CXCL10, CXCL13, and CXCR3 and the endogenous TLR-4 ligand S100A8\/A9 in lymph nodes of patients with adult-onset Still\u2019s disease","volume":"9","author":"Jeon","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_7","first-page":"83","article-title":"Predictive factors and prognosis of macrophage activation syndrome associated with adult-onset Still\u2019s disease","volume":"37","author":"Yang","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rosario, C., Zandman-Goddard, G., Meyron-Holtz, E.G., D\u2019Cruz, D.P., and Shoenfeld, Y. (2013). The hyperferritinaemic syndrome: Macrophage activation syndrome, Still\u2019s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med., 11.","DOI":"10.1186\/1741-7015-11-185"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3346\/jkms.2012.27.6.636","article-title":"Diagnostic value of serum ferritin level in adult-onset Still\u2019s disease","volume":"27","author":"Kim","year":"2012","journal-title":"J. Korean Med. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s40265-018-0956-9","article-title":"Adult-onset Still\u2019s disease: Molecular pathophysiology and therapeutic advances","volume":"78","author":"Sfriso","year":"2018","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset Still\u2019s disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1093\/rheumatology\/keab485","article-title":"Current and emerging biological therapy in adult-onset Still\u2019s disease","volume":"60","author":"Ma","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: Multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Blanco","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset Still\u2019s disease refractory to glucocorticoid treatment: A randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s40744-023-00600-x","article-title":"Risk of macrophage activation syndrome in patients with adult-onset Still\u2019s disease treated with IL-1 and IL-6 inhibitors: A meta-analysis and single-center experience","volume":"10","author":"Adachi","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult-onset Still\u2019s disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat. Rev. Rheumatol"},{"key":"ref_18","first-page":"322","article-title":"Diagnostic value of ferritin and glycosylated ferritin in adult onset Still\u2019s disease","volume":"28","author":"Fautrel","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5","article-title":"Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still\u2019s disease","volume":"44","author":"Kawashima","year":"2001","journal-title":"Arthritis Rheumatol."},{"key":"ref_21","first-page":"2189","article-title":"Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult-onset Still\u2019s disease","volume":"31","author":"Chen","year":"2004","journal-title":"J. Rheumatol."},{"key":"ref_22","first-page":"2622","article-title":"Monitoring neutrophil activation in juvenile and adult-onset Still\u2019s disease by S100A12 serum concentrations","volume":"48","author":"Foell","year":"2003","journal-title":"Arthritis Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult Still\u2019s disease: Manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine"},{"key":"ref_24","first-page":"709","article-title":"Efficacy and safety of treat-to-target strategy studies in rheumatic diseases: A systematic review and meta-analysis","volume":"77","author":"Hao","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ioannidis, J.P.A. (2005). Why most published research findings are false. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020124"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/20\/2630\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:37:40Z","timestamp":1760953060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/20\/2630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":25,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["diagnostics15202630"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15202630","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]}}}